Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 868-876

  Livraghi, Tito ^a   Brambilla, Giorgio ^a   Carnaghi, Carlo ^a   Tommasini, Maurizio A ^a   Torzilli, Guido ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Barcelona Clinic Liver Cancer; chemoembolization; hepatic resection; hepatocellular carcinoma; intra arterial therapy; liver transplantation; molecular targeted therapy; percutaneous ablation therapy; percutaneous ethanol injection; percutaneous radio frequency ablation

Indexed keywords

PLACEBO; SORAFENIB; SUNITINIB;

ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY;

CASE-CONTROL STUDIES; HUMANS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SOFTWARE DESIGN; SURVIVAL RATE;

EID: 78649684215     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21733     Document Type: Article

References (95)

1. Chevret S, Trinchet JC, Mathieu D, et al.: A new prognostic classification for predicting survival in patient with hepatocellular carcinoma. Groupe d'Etude e de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141.
2. CLIP. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-845.
3. Leung TW, Tang AM, Zee B, et al.: Construction of the Chinese Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 2002; 94: 1760-1769.
4. Vauthey JN, Lauwers GJ, Esnaola NF, et al.: Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527-1536.
5. Kawakita T, Shiraki K, Yamanaka Y, et al.: A new prognostic scoring system involving des-gamma-carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma. Int J Oncol 2003; 23: 1115-1120.
6. Makuuchi M, Belghiti J, Belli G, et al.: IHPBA concordant classification of primary liver cancer: Working group report. J Hepatobiliary Pancreat Surg 2003; 10: 26-30.
7. Villa E, Colantoni A, Camma C, et al.: Estrogen receptor classification for hepatocellular carcinoma: Comparison with clinical staging systems. J Clin Oncol 2003; 21: 441-446.
8. Kudo M, Chung H, Haji S, et al.: Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
9. Minagawa M, Ikai I, Matsuyama Y, et al.: Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245: 909-922.
10. Bruix J, Sherman M, Llovet JM, et al.: Clinical management on hepatocellular carcinoma, conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-430.
11. Llovet JM, Burroughs A, Bruix J:, Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
12. Bruix J, Sherman M:, Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
13. Cammà C, Di Marco V, Cabibbo G, et al.: Survival of patients with hepatocellular carcinoma in cirrhosis: A comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75.
14. Farinati F, Sergio A, Baldan A, et al.: Early and very early hepatocellular carcinoma: When and how much to do staging and choice of treatment really matter? A multicenter study. BMC Cancer 2009; 9: 33.
15. Huang GT, Lee PH, Tsang YM, et al.: Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: A prospective study. Ann Surg 2005; 242: 36-42.
16. Chen MS, Li JQ, Zheng Y, et al.: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
17. Lu MD, Kuang M, Liang LJ, et al.: Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: A randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805.
18. Gournay J, Tchuenbou J, Richou C, et al.: Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: A retrospective case-control study with cost analysis. Aliment Pharmacol Ther 2002; 16: 1526-1538.
19. Daniele B, De Sio I, Izzo F, et al.: Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: A CLIP retrospective case-control study. J Clin Gastroenterol 2003; 36: 63-67.
20. Livraghi T, Meloni F, Di Stasi M, et al.: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice ? Hepatology 2008; 47: 82-89.
21. Livraghi T, Golberg SN, Lazzaroni S, et al.: Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection. Radiology 1999; 210: 655-661.
22. Lencioni R, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma: Randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
23. Lin SM, Lin CJ, Lin CC, et al.: Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156.
24. Shiina S, Teratani T, Obi S, et al.: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
25. Brunello F, Veltri A, Carucci P, et al.: Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled study. Scand J Gastroenterol 2008; 43: 727-735.
26. Bouza C, Lopez-Cuadrado T, Alcazar R, et al.: Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009; 9: 31-40.
27. Orlando A, Leandro G, Olivo M, et al.: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524.
28. Capussotti L, Ferrero A, Vigan L, et al.: Portal hypertension: Contraindication to liver surgery. World J Surg 2006; 30: 992-999.
29. Kawano Y, Sasaki A, Kai S, et al.: Short- and long-term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008; 15: 1670-1676.
30. Ishizawa T, Hasegawa K, Aoki T, et al.: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
31. Cucchetti A, Ercolani G, Vivarelli M, et al.: Is portal hypertension a contraindication to hepatic resection ? Ann Surg 2009; 250: 922-928.
32. Imamura H, Seyama Y, Kokudo N, et al.: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-1206.
33. Marelli L, Stigliano R, Triantos C, et al.: Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
34. Doffoel M, Bonnetain F, Bouch Vetter D, et al.: Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients. Eur J Cancer 2008; 44: 528-538.
35. Matsui O, Miyayama S, Sanada JI, et al.: Interventional oncology. New options for interstitial treatments and intravascular approaches: Superselective TACE using iodized oil for HCC: Rationale, technique and outcome. J Hepatobiliary Pancreat Surg 2009; 17: 407-409.
36. Miyayama S, Mitsui T, Zen Y, et al.: Histopatological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009; 39: 374-381.
37. Poon RT, Tso WK, Pang RW, et al.: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-1108.
38. Varela M, Real MI, Burrel M, et al.: Chemoembolisation of hepatocellular carcinoma with drug eluting bead: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481.
39. Grosso M, Vignali C, Quaretti P:, Transarterial chemoembolisation of hepatocellular carcinoma with drug-eluting microspheres: Preliminary results from an Italian multicenter study. Cardiovasc Interv Radiol 2008; 31: 1141-1149.
40. Lammer J, Malagari K, Vogl T, et al.: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
41. Nicolini A, Martinetti L, Crespi S, et al.: Transarterial chemoembolization with epirubicin-eluting-beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332.
42. Maluccio MA, Covey AM, Porat LB, et al.: Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19: 862-869.
43. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with liver cirrhosis. N Engl J Med 1996; 334: 693-699.
44. Volk ML, Vijan S, Marrero JA, et al.: A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transpl 2008; 8: 839-846.
45. Yao FY, Ferrel L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
46. Yao FY, Xiao L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: Validation of the UCSF expanded criteria based on preoperative imaging. Am J Transpl 2007; 7: 2587-2596.
47. Duffy JP, Vardanian A, Benjamin E, et al.: Liver transplantation criteria for hepatocellular carcinoma should be expanded. Ann Surg 2007; 246: 502-511.
48. Fan J, Yang GS, Fu ZR, et al.: Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: A multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-1412.
49. Kneteman NM, Oberholzer J, Al Saghier M, et al.: Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311.
50. Sugawara Y, Tamura S, Makuuchi M:, Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310-312.
51. Kwon CH, Kim DJ, Han YS, et al.: HCC in living donor liver transplantation: Can we expand the Milan criteria ? Dig Dis 2007; 25: 313-319.
52. Li J, Yan LN, Yang J, et al.: Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4170-4176.
53. Mazzaferro V, Llovet JM, Miceli R, et al.: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory study. Lancet Oncol 2009; 10: 35-43.
54. Torzilli G, Donadon M, Marconi M, et al.: Hepatectomy for stage B and C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer Classification. Arch Surg 2008; 143: 1082-1090.
55. Wang JH, Changchien CS, Hu T, et al.: The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma.-Survival analysis of 3892 patients. Eur J Cancer 2008; 44: 1000-1006.
56. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
57. Cheng AL, Kang YK, Chen Z, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
58. Koeberle D, Montemurro M, Samaras P, et al.: Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for clinical cancer research and Swiss Association for the Study of the Liver multicenter phase II trial. Oncologist 2010; 15: 285-292.
59. Thomas MB, Morris JS, Chadha R, et al.: Phase II trial of the combination of bevacizunab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
60. Livraghi T, Meloni F, Frosi A, et al.: Treatment with stem cell differentiation stage factors on intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial. Oncol Res 2005; 15: 1-10.
61. Lopez PM, Villanueva A, Llovet JM:, Systematic review: Evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547.
62. Croce CM:, Oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
63. Inoue Y, Hasegawa K, Ishizawa T, et al.: Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma ? Surgery 2009; 145: 9-19.
64. Kojiro M, Nakashima O:, Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999; 19: 287-296.
65. Kojiro M:, Focus on dysplastic nodules and early hepatocellular carcinoma: An eastern point of view. Liver Transpl 2004; 10: 3A-8A.
66. Okusaka T, Okada S, Ueno H, et al.: Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002; 95: 1931-1937.
67. Nakashima Y, Nakashima O, Tanaka M, et al.: Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003; 26: 142-147.
68. Maeda T, Takenaka K, Taguchi K, et al.: Small hepatocellular carcinoma with minute satellite nodules. Hepatogastroenterology 2000; 47: 1063-1066.
69. Sasaki Y, Imaoka S, Ishiguro S, et al.: Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery 1996; 119: 252-260.
70. Kanai T, Hirohashi S, Upton MP, et al.: Pathology of small hepatocellular carcinoma. Cancer 1987; 60: 810-819.
71. Kim YS, Rhim H, Cho OK, et al.: Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors. Eur J Radiol 2006; 59: 432-441.
72. Ikeda K, Seki T, Umehara H, et al.: Clinicopathologic study of small hepatocellular carcinoma with satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 2007; 31: 485-491.
73. Lam VW, Ng KK, Chock KS, et al.: Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207: 20-29.
74. Cho YK, Kim JK, Kim WT, et al.: Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: A Markov model analysis. Hepatology 2010; 51: 1-7.
75. Livraghi T, Bolondi L, Buscarini L, et al.: No treatment, resection and ethanol injection in hepatocellular carcinoma: A retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol 1995; 22: 522-526.
76. Ryu M, Shimamura Y, Kinoshita T, et al.: Therapeutic results of resection, transcatheter arterial embolization and percutaneous ethanol injection in 3225 patients with hepatocellular carcinoma: A retrospective multicenter study. Jpn J Clin Oncol 1997; 27: 251-257.
77. Cho CM, Tak WY, Kweon YO, et al.: The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma. Korean J Hepatol 2005; 11: 59-71.
78. Hong SN, Lee SY, Choi MS, et al.: Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005; 39: 247-252.
79. Ogihara M, Wong LL, Machi J:, Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: Long-term results. HPB (Oxford) 2005; 7: 214-221.
80. Wakai T, Shirai Y, Suda T, et al.: Long-term outcomes of hepatectomy vs. percutaneous ablation for treatment of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 546-552.
81. Takahashi S, Kudo M, Chung H, et al.: Outcomes of nontransplant potentially curative therapy for early stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation. Dig Dis 2007; 25: 303-309.
82. Hasegawa K, Makuuchi M, Takayama T, et al.: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49: 589-594.
83. Nanashima A, Masuda J, Miuma S, et al.: Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World J Gastroenterol 2008; 14: 58-63.
84. Abu-Hilal M, Primrose JN, Casaril A, et al.: Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 1521-1526.
85. Ueno S, Sakoda M, Kubo F, et al.: Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg 2009; 16: 359-366.
86. Bruix J, Castells A, Bosch J, et al.: Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022.
87. Llovet JM, Fuster J, Bruix J:, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-1440.
88. Geschwind JF, Ramsey DE, Choti MA, et al.: Chemoembolizaton of hepatocellular carcinoma: Results of a meta-analysis. Am J Clin Oncol 2003; 26: 344-349.
89. Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised contolled trial. Lancet 2002; 359: 1734-1739.
90. Cammà C, Schepis F, Orlando A, et al.: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
91. Yao FY:, Liver transplantation for hepatocellular carcinoma: Beyond the Milan criteria. Am J Transpl 2008; 8: 1982-1989.
92. Ponfret EA, Washburn K, Wald C, et al.: Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
93. Jaeck D, Bachellier P, Oussoultzoglou E, et al.: Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: An overview. Liver Transpl 2004; 10: S58-S63.
94. Lu SC:, Where are we in the chemoprevention of hepatocellular carcinoma ? Hepatology 2010; 51: 734-736.
95. Nakashima O, Kojiro M:, Recurrence of hepatocellular carcinoma: Multicentric occurrence or intrahepatic metastases ? J Hepatobiliary Pancreat Surg 2001; 8: 404-409.